Business Wire

Unveiling the HPC Future with xFusion at ISC 2024

Share

xFusion Digital Technologies Co., Ltd. (xFusion) dazzled attendees with its top-of-the-range computing products and solutions at the prestigious ISC High Performance 2024 event, hosted at the Congress Center Hamburg in Germany from May 13th to 15th. During the event, xFusion and fellow participants delved into the realms of AI and high performance computing (HPC) to explore their innovative applications and developmental trends, marking a significant convergence of minds and technologies.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516487957/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: xFusion)

Tab Tang , President of the Computing and Expansion at xFusion, delivered a keynote titled "Reinvent HPC in the Era of AI" during the Vendor Roadmap session on the 15th. He illuminated the pivotal role of smart computing in propelling industrial progress, highlighting the cooling challenges arising from high power and computing density, along with sustainability concerns. This necessitates clusters that are not only high-speed and low-latency but also highly reliable and stable. He also emphasized the transformative impact of AI on scientific endeavors, affirming xFusion's commitment to overcoming these challenges through pioneering software and hardware solutions. With a unified platform for both HPC and AI, xFusion aims to invigorate academic research and reshape the landscape of AI-driven HPC.

This year's ISC witnessed xFusion's spotlight on cutting-edge technologies like AI and HPC, presenting computing advancements characterized by openness, intelligence, eco-friendliness, and high-density. This compelling showcase drew attendees eager to delve deeper into these innovations.

At the event, xFusion proudly introduced FusionPoD for AI, a revolutionary rack-scale liquid-cooling cabinet poised to redefine computing paradigms. With its open architecture and support for diverse computing capabilities, FusionPoD for AI integrates groundbreaking architectural, software, and algorithmic innovations. It offers a fresh perspective by embracing multiple ecosystems, diversity, and low-carbon solutions to cater to the demanding requirements of AI large models and other HPC scenarios. This remarkable product delivers an unparalleled computing density of 64 GPUs and features a 100% liquid cooling native design with an impressively low pPUE of 1.06. xFusion also introduced the AI Space accelerator to both partners and customers, promising to expedite their AI application development and deployment.

xFusion stole the spotlight at ISC 2024 by showcasing its FusionOne HPC solution tailored for diverse HPC applications in education, scientific research, and manufacturing simulation. This state-of-the-art offering boasts adaptive characteristics, ensuring efficient, secure, reliable, and easily manageable operations. Notably, FusionOne HPC has already made waves with its deployment in the Weiming No. 2 Cluster at Peking University in 2023. This implementation has addressed the diverse needs of various disciplines, facilitating large-scale data processing and scientific computing while simultaneously reducing power consumption and fostering green research initiatives.

Beyond technological excellence, xFusion leads the charge in delivering comprehensive global business support through its dedicated team, bolstering remote O&M, cluster systems, and open architectural frameworks. Collaborating closely with partners, xFusion drives continuous innovation, fostering a thriving and sustainable HPC ecosystem. The current partnership with Bank Neo Commerce (BNC) in Indonesia marks a pivotal step in revolutionizing digital banking services. By offering agile, secure, and scalable digital infrastructure, xFusion empowers BNC to handle increasing transaction volumes and enhance customer interactions, fueling ongoing innovation and development in local digital banking services. FusionOnline, xFusion's remote intelligent O&M platform, is facilitating remote O&M in Europe, streamlining maintenance efforts while ensuring the long-term stability of user services.

Guided by the vision and mission of "Let Computing Serve You Better", xFusion has expanded its reach to over 100 countries and regions, cementing its status as a premier provider of computing infrastructures and services globally.

Looking to the future, xFusion remains optimistic about the potential of HPC to revolutionize industries and drive transformative innovation. In the era of AI, our ongoing contributions to the advancement of HPC underscore our commitment to shaping a brighter, more efficient, and interconnected world powered by our top-notch computing products and solutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Henry Chen | Senior Brand Manager
chenjundai@xfusion.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia23.6.2024 04:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today presented positive results from its Phase 2b, randomized, double-blind, placebo-controlled study evaluating the safety, tolerability and efficacy of mezagitamab (TAK-079) in patients with persistent or chronic primary immune thrombocytopenia (ITP), a rare immune-mediated bleeding disorder. ITP is characterized by the accelerated destruction of platelets in blood, resulting in a decreased platelet count and an increase of bleeding that can be debilitating. These data (Abstract #LB 01.1) were presented at the oral Late-Breakthrough Session at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH) in Bangkok, Thailand. Takeda plans to initiate a global Phase 3 trial of mezagitamab in patients with ITP in the second half of FY2024. The TAK-079-1004 trial (NCT04278924) evaluated three different doses of subcutaneous mezagitamab (100mg, 300mg and 600mg) versus placebo, given once weekly for eight weeks in patients with chronic or

PMC Biogenix Announces Expansion and Restructure21.6.2024 23:00:00 CEST | Press release

PMC Biogenix, the leading sustainable producer of specialty fatty amides and high-value biobased products, announces the construction and expansion of its new Armoslip® facility in Gyeongju, South Korea allowing for a production capacity increase of 50%. Construction will begin late 2024 with new supply available by mid-2026. “We are excited to announce plans to build a new facility in Gyeongju. This investment will allow us to significantly increase production capacity to meet growing customer demand for our Armoslip products,” said Debtosh Chakrabarti, President, PMC Group N.A., Inc. Adding, “This project solidifies our commitment as the industry leader, delivering products and solutions to our customers, as well as to the local Gyeongju community. We appreciate the continued support of the Gyeongju, South Korea local government, community, and our customers.” As part of PMC’s ongoing commitment of ensuring long-term sustainability and success of the Biogenix business world-wide, a c

Esri Technology Used By ALS Therapy Development Institute to Map Clinical Trials21.6.2024 22:58:00 CEST | Press release

The ALS Therapy Development Institute (ALS TDI), a nonprofit biotech dedicated to ending amyotrophic lateral sclerosis (ALS), has used mapping technology from Esri, the global leader in location intelligence, to develop the ALS Trial Navigator. The new tool is designed to simplify and streamline the process by which people with ALS and their caretakers learn about current ALS studies. With the ALS Trial Navigator users can now explore an interactive map to find locations where applicable clinical trials are taking place. They can also receive a customized map based on their preferences and status of their ALS. "ALS Trial Navigator helps people living with ALS, those that might face it in the future, and researchers looking to enroll trials by educating the community and providing information about current studies all around the world," said Dr. Nadia Sethi, ALS TDI's director of community engagement, who oversaw the Navigator's design and creation. Once a person is diagnosed with ALS,

Lifezone Metals Announces Voting Results from its 2024 Annual General Meeting21.6.2024 22:30:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) announces the results of voting by shareholders at its 2024 Annual General Meeting (the “AGM”) held today in the Isle of Man. The ordinary resolutions below were passed by shareholders, with voting results as follows: Ordinary Resolutions For % For Against % Against Abstain % Abstain To receive the Company’s accounts for the financial year ended December 31, 2023 60,456,134 100.00% 0 0.00% 264 0.00% To re-elect John Dowd as a Class I Director of the Company 60,375,930 99.87% 79,177 0.13% 1,291 0.00% To re-elect Govind Friedland as a Class I Director of the Company 59,713,208 98.77% 79,319 0.13% 663,871 1.10% To re-elect Ambassador Mwanaidi Maajar as a Class I Director of the Company 60,314,469 99.77% 81,886 0.14% 60,043 0.10% A total of 60,456,398 or 75.57% of Lifezone Metals Ordinary Shares outstanding were represented at the AGM. If you would like to sign up for Lifezone Metals news alerts, please register here. About Lifezone Metals At Lifezone Me

Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer21.6.2024 22:00:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved FRUZAQLA (fruquintinib) as a monotherapy indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available standard therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapies, anti-VEGF agents, and anti-EGFR agents, and who have progressed on or are intolerant to treatment with either trifluridine-tipiracil or regorafenib. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on April 25, 2024, and approval by the U.S. Food and Drug Administration (FDA) for adults with mCRC who have been previously treated with oxaliplatin- and irinotecan-based regimens on November 8, 2023.1,2 “People living with metastatic colorectal cancer face numerous difficulties, stemming both from their illness and the adverse effects of therapies. Given the complex nature of the d

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye